

# Genmab Proprietary Knock-Your-Socks-Off Pipeline

## Potential INDs in next 4 years

Technology	product	2017	2018	2019	2020
HexaBody	HexaBody-DR5/DR5	■			
DuoBody	DuoBody-CD3xCD20	■			
HexaBody	HexaBody-X			■	
DuoBody-ADC	DuoBody-XxY-ADC			■	
DuoBody	DuoBody-CD3xX			■	
Immuno-Oncology [>10 progr.]*	DuoBody-A		■		
	DuoBody-B			■	
	DuoBody-C			■	
	DuoBody-D				■
	DuoBody-E				

\*: Aduro Biotech & BioNTech

Pre-clinical pipeline targeting at least 4 leapfrog INDs in next 4 years